歌礼制药-B（01672）早盘涨超8%，截至发稿，股价上涨8.07%，现报10.31港元，成交额926.46万港元。
近日，歌礼制药-B发布公告，ASC30用于长期体重管理的全球III期临床项目已完成首例受试者给药。ASC30是一款歌礼专有的、正在临床研究中的每日一次口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂，开发用于长期体重管理和糖尿病治疗。
公告称，歌礼制药-B预计将于2028年第三季度公布AURORA III期临床项目的顶线数据。公司预计于2028年底向美国食品药品监督管理局（FDA）递交新药上市申请（NDA），及于2029年初向欧洲药品管理局（EMA）递交上市许可申请（MAA）。歌礼拥有稳健的资产负债表和充足的在手现金，足以覆盖该项目计划在美国和欧洲递交的监管申请，并可支持公司运营至2029年。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.